SEC-sourced researchBeta

KPTI

Karyopharm Therapeutics Inc.

US markets

Data passport

CIK: 0001503802
Exchange: Nasdaq
Business activity: — · SIC 2834
Financial inputs: 6/6
Filing date: Oct 2, 2026
SEC registry record: Operating company

Last updated: Oct 8, 2026, 9:09 AM UTCSEC company ticker catalog ↗SEC Financial Statement Data Sets ↗SEC investment company series and class registry ↗

Annual financial history

Up to three published annual periods. The chart shows financial statement amounts; missing observations are not connected. Each company chart uses its own scale; compare amounts in the table.

Chart metric

KPTI · Exact amounts and source periods · USD
Period end	Revenue	Filing date
December 2023	146,033,000.0000	Feb 13, 2026
December 2024	145,237,000.0000	Feb 13, 2026
December 2025	146,067,000.0000	Feb 13, 2026

Annual periods · USD

Period end	Revenue	Net income	Operating cash flow	Total assets	Total liabilities	Filing date
December 2025	146,067,000.0000	-196,039,000.0000	-75,369,000.0000	108,416,000.0000	401,342,000.0000	Feb 13, 2026
December 2024	145,237,000.0000	-76,422,000.0000	-127,486,000.0000	164,418,000.0000	350,435,000.0000	Feb 13, 2026
December 2023	146,033,000.0000	-143,099,000.0000	-92,723,000.0000	—	—	Feb 13, 2026

Financial inputs behind the calculation

Financial inputs	USD	Period end	Filing date	Form
RevenueRevenueFromContractWithCustomerExcludingAssessedTax	$146.07M	December 2025	Feb 13, 2026	10-K
Previous period revenueRevenueFromContractWithCustomerExcludingAssessedTax	$145.24M	December 2024	Feb 13, 2026	10-K
Net incomeNetIncomeLoss	-$196.04M	December 2025	Feb 13, 2026	10-K
Operating cash flowNetCashProvidedByUsedInOperatingActivities	-$75.37M	December 2025	Feb 13, 2026	10-K
Total assetsAssets	$108.42M	December 2025	Feb 13, 2026	10-K
Total liabilitiesLiabilities	$401.34M	December 2025	Feb 13, 2026	10-K

New filings

Explore methodology ↗